Skip to main content

Security report for glenmarkpharma.ca

Glenmark Pharmaceuticals · Healthcare · Canada

Medium risk. 5 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

67/100

Risk levelMedium

0–100, higher is better. How it is calculated

Glenmark Pharmaceuticals Ltd. operates a Canadian website providing pharmaceutical products and patient resources, focusing on generic drugs. The company is part of a global pharmaceutical group with a presence in multiple countries including the US and India. The website is built on WordPress with a modern tech stack including Google Analytics and Tag Manager for tracking. The site is professionally designed with good navigation and mobile optimization, targeting patients and healthcare professionals in Canada. Security posture is adequate with HTTPS enforced and domain transfer protection, but lacks DNSSEC and explicit security policies. Privacy compliance is limited due to absence of cookie consent mechanisms and detailed privacy policies. Overall, the website reflects a credible and established pharmaceutical business with room for improvement in security and privacy transparency.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching glenmarkpharma.ca

This scan found 25 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
45
Email security
70
DNS health
70
Network security
100
GDPR outside view
53
Average
67

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The company holds a strong market position as a global pharmaceutical manufacturer with a dedicated Canadian presence. Its business model centers on manufacturing and distributing generic pharmaceutical products. The website supports patient engagement through adverse event reporting and educational content. The absence of direct contact emails or phone numbers on the homepage suggests a controlled communication channel, likely via contact forms. The company leverages partnerships and subsidiaries to extend its market reach. The digital presence is mature but could enhance compliance and security disclosures to align with industry best practices.

Security posture

The website employs HTTPS with a valid SSL certificate and domain transfer protection, indicating a baseline security posture. However, the lack of DNSSEC implementation and missing security headers reduce the overall security robustness. No explicit incident response or security policies are published, which may impact trust and compliance. The use of third-party analytics introduces moderate user tracking, but an opt-out mechanism is present. No critical vulnerabilities or exposed sensitive data were detected in the analysis. Recommendations include enabling DNSSEC, adding security headers, and publishing security and incident response policies to improve security maturity.

Recommendations

  1. Enable DNSSEC on the domain to protect against DNS spoofing and improve domain security.
  2. Implement comprehensive cookie consent mechanisms and update privacy policies to ensure GDPR and other privacy regulation compliance.
  3. Add security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to enhance protection against common web attacks.
  4. Publish clear security and incident response policies including contact channels for reporting security incidents.
  5. Regularly audit third-party scripts and tracking tools to minimize privacy risks and improve transparency.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Glenmark Pharmaceuticals
Description
Glenmark Pharmaceuticals Ltd. operates in Canada providing pharmaceutical products including generic drugs. The website offers information about the company, its leadership, products, patient resources, and contact details.
Key services
Generic pharmaceutical products, Patient information and support, Adverse event reporting
Content quality
good
Branding
consistent

Technology

Stack
WordPress, jQuery, Google Tag Manager, Google Analytics, Typekit Fonts, Slick Carousel, Motion UI, Foundation CSS
Frameworks
Foundation
Platforms
WordPress
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
70/100
Good practices seen
  • HTTPS enforced
  • ClientTransferProhibited domain status

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
basic

Advertising

Marketing tools
MonsterInsights
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a WordPress-based pharmaceutical company site for Canadian market.
  2. Content is professional and relevant to healthcare and pharmaceuticals.
  3. No privacy or cookie policy banners detected, indicating potential compliance gap.
  4. No explicit security or incident response policies published.
  5. Use of Google Analytics and Tag Manager for tracking with opt-out mechanism.
  6. No DNSSEC enabled, which is a recommended security improvement.
  7. WHOIS data is transparent and consistent with business identity.
Technical notes

Notes

The website is built on WordPress CMS using a combination of modern front-end libraries and frameworks including jQuery, Foundation CSS, and Slick Carousel. It integrates Google Tag Manager and Google Analytics for user tracking and performance measurement. The site is mobile optimized with responsive design and uses Typekit for custom fonts. Performance is moderate with room for optimization. The hosting provider is not explicitly identified but domain registrar is Go Get Canada Domain Registrar Ltd. The site lacks DNSSEC and some security headers, which are technical risks. Overall, the technical infrastructure supports a professional and functional web presence but could benefit from enhanced security and privacy technical controls.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with glenmarkpharma.ca. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review glenmarkpharma.ca.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.